Growth hormone-secreting pituitary adenomas that cause acromegaly arise as monoclonal
expansions of differentiated somatotroph cells and are usually sporadic. They are almost …

Acromegaly is associated with significant morbidity and mortality if it is not appropriately
treated. In addition to insulin-like growth factor 1 and growth hormone normalization as well …

Background Despite biochemically responding to injectable somatostatin receptor ligands
(iSRLs), many patients with acromegaly experience treatment burdens. We aimed to assess …

Objective Acromegaly is associated with somatic disfigurements which impair self-
perception of well-being and quality of life. Nowadays, limited data are available on the …

Objective To assess differences in body image concerns among women with and without
polycystic ovary syndrome (PCOS). Design This is a systematic review and meta-analysis …

Although metabolic alterations, hypertension, and the early stages of cardiomyopathy may
be reversible after cure or disease control, many other complications such as …

Acromegaly is a rare and insidious disease characterized by chronic excess growth
hormone, leading to various morphological changes and systemic complications. Despite its …

Acromegaly is a rare disease caused by a growth hormone excess, usually due to a
secreting pituitary adenoma. Somatostatin receptor ligands (SRL) are the mainstay of …

Purpose To report the effects of pegvisomant (PEGV) treatment on patient-reported
outcomes in acromegaly patients. Methods We conducted an extension study of an open …

Purpose Acromegaly is a rare chronic disease characterized by systemic comorbidity and
reduced quality of life. Although achieving biochemical control has always been the primary …